« Back to Medicines list

Maalox 400mg/400mg Chewable Tablets

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 05/12/17

files-icon(Click to Download)

XPIL

Summary of Product Characteristics last updated on medicines.ie: 8/12/2017
print

Print ViewKeyword Search SmPC

SANOFI

SANOFI

Company Products

Medicine NameActive Ingredients
Medicine Name Adenocor Active Ingredients Adenosine
Medicine Name Amaryl 1mg Tablets Active Ingredients Glimepiride
Medicine Name Amaryl 3mg Tablets Active Ingredients Glimepiride
Medicine Name Anthisan Cream Active Ingredients Mepyramine Maleate
Medicine Name Apidra 100 units/ml solution for injection in a cartridge Active Ingredients Insulin Glulisine
Medicine Name Apidra 100 Units/ml solution for injection in a vial Active Ingredients Insulin Glulisine
Medicine Name Apidra SoloStar 100 units/ml solution for injection in a pre-filled pen Active Ingredients Insulin Glulisine
Medicine Name Aprovel 150mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 300mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 75mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Arava 10 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Arava 20 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Bisolvon Oral Solution Active Ingredients Bromhexine hydrochloride
Medicine Name Brolene 0.1%w/v Eye Drops Solution Active Ingredients Propamidine Isethionate
Medicine Name Brolene 0.15% w/w Eye Ointment Active Ingredients Dibromopropamidine Isethionate
Medicine Name Buscopan 10 mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Ampoules Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Rx 10mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Calcium Resonium Active Ingredients Calcium polystyrene sulfonate
Medicine Name Cerubidin 20mg Powder for Solution for Injection Active Ingredients daunorubicin hydrochloride
Medicine Name Cidomycin Paediatric 20mg/2ml Solution For Injection Active Ingredients Gentamicin sulfate
Medicine Name Claforan Powder for Solution for Injection 1g Active Ingredients Cefotaxime sodium
Medicine Name Claforan Powder for Solution for Injection 500mg Active Ingredients Cefotaxime sodium
Medicine Name Clexane 10,000 IU (100mg)/1ml Solution for Injection Active Ingredients Enoxaparin sodium
Medicine Name Clexane 2,000 IU (20 mg) /0.2 mL Solution for Injection Active Ingredients Enoxaparin sodium
1 - 0 of 178 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 8 December 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Supply through pharmacy only

Updated on 8 December 2017 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.5 added:-

Urine alkalinisation secondary to administration of magnesium hydroxide may modify excretion of some drugs; thus, increased excretion of salicylates has been seen.

Section 4.8 amendments:-

Immune system disorders -  amended:-

 Frequency unknown to Not known

Gastrointestinal disorders – added:-

Not known: abdominal pain

 

Metabolism and nutrition disorders

Added:- Very rare: hypermagnesemia including observations after prolonged administration to patients with renal impairment.

Amended:- from Frequency unknown to Not known:

 Removed:- hypermagnesemia,

Updated on 5 December 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 5 December 2017 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 20 May 2015 PIL

Reasons for updating

  • Change to name of manufacturer

Updated on 17 September 2014 PIL

Reasons for updating

  • Change of contraindications
  • Change to instructions about overdose
  • Change to side-effects
  • Change to further information section

Updated on 28 August 2014 SmPC

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 4.3 changed from allergic to hypersensitive.
Section 4.4 information included on intestinal obstruction and ileus in patients at higher risk such as those with renal impairment and information included on aluminium hydroxide not being well absorbed by the gastrointestinal tract.
Section 4.5 updated to include cefdinir and cefpodoxime.  New paragraph on caution when concomitantly used with polystyrene sulfonate.
Section 4.6 updated to include 'Because of the limited maternal absorbtion when used as recommended, alumiunium hydroxide and magnesium sales combinations are considered as compatible with lactation.'
Section 4.8 updated to include immune system disorders and metabolism and nutrition disorders. PV Legislation wording included.
Section 4.9 new paragraphs on Signs and Symptoms and Management.

Updated on 1 November 2013 PIL

Reasons for updating

  • Addition of manufacturer

Updated on 17 January 2013 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 28 August 2012 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 7 updated to include 'Sanofi' as a trading style

Updated on 20 January 2012 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company


Section 2: Update of excipients Listing
Section 3: Change of tablet description
Section 6.1: Update of Excipient
Section 6.3: Change in shelf-life

Updated on 7 May 2010 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Change to product name

Updated on 6 May 2010 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 2 September 2009 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 27 August 2009 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.4 - Special warnings and precautions for use
  • Correction of spelling/typing errors

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Correction of typing errors & update of excipient warning.

Updated on 10 October 2008 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 8 October 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Supply through pharmacy only

Updated on 9 August 2007 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Supply through pharmacy only